NO323448B1 - Hydrokloridsalter av 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion, fremgangsmate for fremstilling derav samt farmasoytisk preparat omfattende hydrokloridsaltet. - Google Patents

Hydrokloridsalter av 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion, fremgangsmate for fremstilling derav samt farmasoytisk preparat omfattende hydrokloridsaltet. Download PDF

Info

Publication number
NO323448B1
NO323448B1 NO20024307A NO20024307A NO323448B1 NO 323448 B1 NO323448 B1 NO 323448B1 NO 20024307 A NO20024307 A NO 20024307A NO 20024307 A NO20024307 A NO 20024307A NO 323448 B1 NO323448 B1 NO 323448B1
Authority
NO
Norway
Prior art keywords
hydrochloride
provides
compound
methyl
pyridyl
Prior art date
Application number
NO20024307A
Other languages
English (en)
Norwegian (no)
Other versions
NO20024307L (no
NO20024307D0 (no
Inventor
Andrew Simon Craig
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of NO20024307L publication Critical patent/NO20024307L/no
Publication of NO20024307D0 publication Critical patent/NO20024307D0/no
Publication of NO323448B1 publication Critical patent/NO323448B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20024307A 2000-03-14 2002-09-09 Hydrokloridsalter av 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion, fremgangsmate for fremstilling derav samt farmasoytisk preparat omfattende hydrokloridsaltet. NO323448B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0006133.3A GB0006133D0 (en) 2000-03-14 2000-03-14 Novel pharmaceutical
PCT/GB2001/001131 WO2001068646A1 (en) 2000-03-14 2001-03-14 Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione

Publications (3)

Publication Number Publication Date
NO20024307L NO20024307L (no) 2002-09-09
NO20024307D0 NO20024307D0 (no) 2002-09-09
NO323448B1 true NO323448B1 (no) 2007-05-07

Family

ID=9887600

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024307A NO323448B1 (no) 2000-03-14 2002-09-09 Hydrokloridsalter av 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion, fremgangsmate for fremstilling derav samt farmasoytisk preparat omfattende hydrokloridsaltet.

Country Status (30)

Country Link
US (2) US7074811B2 (cs)
EP (1) EP1265893B1 (cs)
JP (1) JP2003527393A (cs)
KR (1) KR100746813B1 (cs)
CN (1) CN100516062C (cs)
AP (1) AP1545A (cs)
AT (1) ATE302202T1 (cs)
AU (1) AU777987B2 (cs)
BG (1) BG65924B1 (cs)
BR (1) BR0108870A (cs)
CA (1) CA2403109A1 (cs)
CZ (1) CZ20023074A3 (cs)
DE (1) DE60112729T2 (cs)
DK (1) DK1265893T3 (cs)
DZ (1) DZ3316A1 (cs)
EA (1) EA005115B1 (cs)
ES (1) ES2243458T3 (cs)
GB (1) GB0006133D0 (cs)
HU (1) HUP0300158A3 (cs)
IL (2) IL151425A0 (cs)
MA (1) MA25658A1 (cs)
MX (1) MXPA02008972A (cs)
NO (1) NO323448B1 (cs)
NZ (1) NZ520910A (cs)
OA (1) OA12229A (cs)
PL (1) PL357283A1 (cs)
SK (1) SK286399B6 (cs)
UA (1) UA73974C2 (cs)
WO (1) WO2001068646A1 (cs)
ZA (1) ZA200207292B (cs)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0021865D0 (en) * 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0023971D0 (en) * 2000-09-29 2000-11-15 Smithkline Beecham Plc Novel pharmaceutical
KR20040062963A (ko) * 2001-11-21 2004-07-09 스미스클라인비이참피이엘시이 5-(4-(2-(n-메틸-n-(2-피리딜)아미노)에톡시)벤질)티아졸리딘-2,4-디온 벤젠술포네이트, 그의 제조 방법, 그의다형체 ⅰ, ⅱ 및 ⅲ, 및 제약상 활성 성분으로서의 그의용도
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
WO2006018853A2 (en) 2004-08-19 2006-02-23 Hetero Drugs Limited Novel polymorphs of efavirenz
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
CN103951667A (zh) 2006-05-04 2014-07-30 勃林格殷格翰国际有限公司 多晶型
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
US20090076093A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched rosiglitazone
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR20190016601A (ko) 2008-08-06 2019-02-18 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
CA2736421A1 (en) 2008-09-10 2010-03-18 Boehringer Ingelheim International Gmbh Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
US20100158821A1 (en) * 2008-12-22 2010-06-24 Eastman Chemical Company Antimicrobial agents, compositions and products containing the same, and methods of using the compositions and products
CA2745037C (en) 2008-12-23 2020-06-23 Boehringer Ingelheim International Gmbh Salt forms of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8(3-(r)-amino-piperidin-1-yl)-xanthine
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
US8106111B2 (en) * 2009-05-15 2012-01-31 Eastman Chemical Company Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions
EA034869B1 (ru) 2009-11-27 2020-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин
CN102946875A (zh) 2010-05-05 2013-02-27 贝林格尔.英格海姆国际有限公司 组合疗法
ES2802243T3 (es) 2010-06-24 2021-01-18 Boehringer Ingelheim Int Terapia para la diabetes
AR083878A1 (es) 2010-11-15 2013-03-27 Boehringer Ingelheim Int Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US20130303462A1 (en) 2012-05-14 2013-11-14 Boehringer Ingelheim International Gmbh Use of a dpp-4 inhibitor in podocytes related disorders and/or nephrotic syndrome
ES2929025T3 (es) 2012-05-14 2022-11-24 Boehringer Ingelheim Int Linagliptina, un derivado de xantina como inhibidor de dpp-4, para su uso en el tratamiento del SRIS y/o de la septicemia
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3110449B1 (en) 2014-02-28 2023-06-28 Boehringer Ingelheim International GmbH Medical use of a dpp-4 inhibitor
AU2017276758A1 (en) 2016-06-10 2018-11-08 Boehringer Ingelheim International Gmbh Combinations of Linagliptin and metformin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US120078A (en) * 1871-10-17 Improvement in revolving flower-stands
US137940A (en) * 1873-04-15 Improvement in elevators
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
GB9413975D0 (en) * 1994-07-11 1994-08-31 Fujisawa Pharmaceutical Co New heterobicyclic derivatives
GB9124513D0 (en) 1991-11-19 1992-01-08 Smithkline Beecham Plc Novel process
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5708012A (en) 1995-04-28 1998-01-13 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
EA003144B1 (ru) 1997-06-18 2003-02-27 Смитклайн Бичам Плс Способ лечения диабета тиазолидиндионом и метформином
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
GB9909075D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
GB9909041D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
CA2370258A1 (en) 1999-04-23 2000-11-02 Paul David James Blackler Thiazolidinedione derivative and its use as antidiabetic
DE60004196T2 (de) 1999-04-23 2004-04-15 Smithkline Beecham Plc, Brentford Polymorph von 5-[4-[2-(n-methyl-n-(2-pyrdyl)amino)äthoxy]benzyl]thiazolidin-2,4-dion, maleinsäuresalz
HUP0200937A3 (en) 1999-04-23 2004-03-29 Smithkline Beecham Plc Thiazolidinedione derivative and its use as antidiabetic and process for preparation thereof
HU225919B1 (en) 1999-12-18 2007-12-28 Richter Gedeon Nyrt Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
CN1277965A (zh) 2000-06-14 2000-12-27 中国医药研究开发中心 盐酸罗格列酮及其应用
GB0021865D0 (en) 2000-09-06 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical

Also Published As

Publication number Publication date
AU777987B2 (en) 2004-11-11
HUP0300158A3 (en) 2005-04-28
WO2001068646A1 (en) 2001-09-20
BG107012A (bg) 2003-04-30
NO20024307L (no) 2002-09-09
DE60112729T2 (de) 2006-06-08
DK1265893T3 (da) 2005-11-14
ATE302202T1 (de) 2005-09-15
PL357283A1 (en) 2004-07-26
CA2403109A1 (en) 2001-09-20
KR100746813B1 (ko) 2007-08-06
JP2003527393A (ja) 2003-09-16
EA005115B1 (ru) 2004-10-28
SK286399B6 (sk) 2008-09-05
SK13302002A3 (sk) 2003-02-04
BR0108870A (pt) 2002-12-17
ES2243458T3 (es) 2005-12-01
CZ20023074A3 (cs) 2003-02-12
EP1265893B1 (en) 2005-08-17
UA73974C2 (en) 2005-10-17
IL151425A0 (en) 2003-04-10
EA200200975A1 (ru) 2003-02-27
DZ3316A1 (fr) 2001-09-20
EP1265893A1 (en) 2002-12-18
NZ520910A (en) 2004-06-25
DE60112729D1 (de) 2005-09-22
IL151425A (en) 2009-08-03
ZA200207292B (en) 2003-05-06
AU4084301A (en) 2001-09-24
HK1052502A1 (en) 2003-09-19
HUP0300158A2 (en) 2003-05-28
BG65924B1 (bg) 2010-05-31
CN100516062C (zh) 2009-07-22
MXPA02008972A (es) 2003-02-10
US7074811B2 (en) 2006-07-11
MA25658A1 (fr) 2002-12-31
AP2002002600A0 (en) 2002-09-30
NO20024307D0 (no) 2002-09-09
OA12229A (en) 2003-11-07
AP1545A (en) 2006-01-12
US20040152901A1 (en) 2004-08-05
CN1358184A (zh) 2002-07-10
KR20020079998A (ko) 2002-10-21
US20050267162A1 (en) 2005-12-01
GB0006133D0 (en) 2000-05-03

Similar Documents

Publication Publication Date Title
NO323448B1 (no) Hydrokloridsalter av 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]benzyl]tiazolidin-2,4-dion, fremgangsmate for fremstilling derav samt farmasoytisk preparat omfattende hydrokloridsaltet.
NO317255B1 (no) Substituert tiazolidinderivat, fremgangsmate for fremstilling og anvendelse derav
US20070191435A1 (en) Hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
NO320587B1 (no) Polymorf, anvendelse og fremstilling derav, samt farmasoytisk preparat.
NO320609B1 (no) Hydroklorid-hydrat, anvendelse og fremstilling derav, samt farmasoytisk preparat.
NO320573B1 (no) Hydroklorid-hydrater, anvendelse og fremstilling derav, samt farmasoytisk preparat.
NO324595B1 (no) Tartratsalt av tiazolidindionderivat, fremgangsmate for fremstilling derav, anvendelse derav og farmasoytisk preparat omfattende saltet
US20040014790A1 (en) Tartrate salt of thiazolidinedione derivative
KR20030022356A (ko) 티아졸리딘디온 유도체의 타르타르산염
NO324970B1 (no) Farmasoytisk preparat omfattende 5-[4-[2-(N-metyl-N-(2-pyridyl)amino)etoksy]-benzyl]tiazolidin-2,4-dionkaliumsalt samt anvendelse av saltet
US20040102485A1 (en) Tartrate salt of thiazolidinedione derivative
MXPA03001083A (es) Farmaceutico novedoso .
HK1052502B (en) Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
WO2003050111A1 (en) Toluenesulfonate salts of a thiazolidinedione derivative
WO2003050112A1 (en) Toluenesulfonate hydrates of a thiazolidinedione derivative
WO2003050114A1 (en) Sulfate salt of a thiazolidinedione derivative
HK1105818A (en) A thiazolidinedione derivative and its use as antidiabetic

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees